M&A / Deals Daiichi Sankyo and Waiv partner for ADC biomarkers Pharmaceutical TechnologyDaiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.OncologyRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaceutical Technology Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Halozyme and Oruka sign agreement for Hypercon technologyNext: Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
